This biotechnology company utilizes machine learning to analyze comprehensive tumor genome data, including dark genome alterations, to identify patient cohorts and validate therapeutic targets. By focusing on synthetic lethality, the company aims to develop drugs that effectively target tumors with inactivated suppressor genes, addressing the limitations of current targeted therapies.
Funding
$120K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current targeted cancer therapies primarily focus on inhibiting oncogenes, but many oncogenes and tumors with inactivated suppressor genes remain difficult to target effectively. Existing methods often fail to fully utilize comprehensive tumor genome data, including alterations in the dark genome, for patient selection and target validation.
Solution
This biotechnology company leverages machine learning to analyze complete tumor genome data, encompassing both exome and dark genome alterations, to improve patient selection and validate therapeutic targets. By integrating target validation with cohort selection, the company aims to identify patient-relevant models using real patient data. The company's primary therapeutic strategy focuses on synthetic lethality, enabling the development of drugs that target tumors with inactivated suppressor genes and previously undruggable oncogenes. This approach seeks to overcome the limitations of current targeted medicines by exploiting tumor vulnerabilities.
Target Audience
The primary audience includes pharmaceutical companies and research institutions focused on developing novel cancer therapeutics and personalized medicine approaches.
Features
- Machine learning-driven analysis of comprehensive tumor genome data, including exome and dark genome alterations.
- Patient selection based on real patient data to identify relevant validation models.
- Focus on synthetic lethality to target tumors with inactivated suppressor genes.
- Integration of target validation with cohort selection for a coherent therapeutic strategy.